Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce ...
-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) --BTK inhibition through the SH2 domain results in ...
A proprietary Src homology 2 (SH2) platform of integrated technologies was applied for the discovery of REX-7117 and REX-5376, two highly potent, selective and orally available SH2 domain-targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback